A Phase 2 interventional study of VPD-737 and Placebo in Chronic Pruritus, sponsored by Vyne Therapeutics Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-13.
Sponsored by Vyne Therapeutics Inc. · Phase 2, Interventional, and Treatment
A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
The sensation of itch is transmitted to the brain through the nervous system Several chemicals are involved in transmitting this signal This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial The trial will involve once daily pills for 6 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period Patients will also be monitored for safety and will have blood taken for testing and several points during the trial Overall participation will last about 12 weeks
354 studies on the registry are indexed under Pruritus; 74 are open to participants now.
This study's enrollment of 257 is above the median of 60 across 294 interventional studies indexed under Pruritus.
Browse Pruritus studies →Vyne Therapeutics Inc. is the lead sponsor of 32 studies on the registry; none are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
0.25 mg of VPD-737 daily by mouth for 42 days
Drug: VPD-737
1 mg VPD-737 taken daily by mouth for 42 days
Drug: VPD-737
5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
Drug: VPD-737
placebo tablets to be taken daily by mouth for 42 days
Drug: Placebo
NK1 Receptor Antagonist
Also known as: Serlopitant
Visual Analog Scale
Time frame: 6 weeks
Verbal Response Scale
Time frame: 6 weeks
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vyne Therapeutics Inc.